Related Experiment Video
Updated: Jul 12, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and
Qunqun Jiang1, Junru Liu2, Zhuoqi Li3
1Dermatological Department, The 970th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, Weihai, Shandong, P.R. China.
Background:
This study was designed to assess the risk of programmed cell death-1 (PD-1) or programmed cell death ligand 1 (PD-L1) related rash in various situations.
Methods:
Guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses, data on rash in clinical trials related to PD-1 or PD-L1 were collected to comprehensively evaluate its incidence risk in various situations.
Results:
Ninety-five clinical trials, divided into 12 groups according to treatment regimens, were enrolled for the final comprehensive assessments and analyses. Compared with chemotherapy or placebo alone, both PD-1 and PD-L1 inhibitors increased the risk of developing rashes for all grades (odds ratio [OR] = 1.61, P = .0003; OR = 2.94, P < .00001). Whether used in combination with chemotherapy or other types of immunosuppressants, similar risk trends were observed (OR = 2.42, P < .00001; OR = 2.11, P = .0007; OR = 4.49, P < .00001; OR = 5.15, P = .0006; OR = 3.16, P = .0002).
Conclusion:
Both PD-1 and PD-L1 increased the risk of rash occurrence, especially when used in combination with other immunosuppressive antitumor drugs.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cancer Survival Analysis

